Top Australian (ASX) Pharmaceuticals & Biotech Growth Stocks

Top Australian (ASX) Pharmaceuticals & Biotech Growth Stocks

UPDATED Aug 05, 2022

What are the best Australian (ASX) Pharmaceuticals & Biotech Growth Stocks?

According to our Simply Wall St analysis these are the best Australian Pharmaceuticals & Biotech growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

3 companies meet this criteria in the Australian market

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CUV's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 17% below our estimate of its fair value

  • Earnings are forecast to grow 30.58% per year

  • Earnings grew by 15.2% over the past year

Risks

  • Significant insider selling over the past 3 months

View all Risks and Rewards

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: IMM is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 91.4% below our estimate of its fair value

  • Earnings are forecast to grow 62.89% per year

Risks

  • Does not have meaningful revenue (A$4M)

View all Risks and Rewards

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: ARX is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 38% below our estimate of its fair value

  • Earnings are forecast to grow 87.98% per year

Risks

No risks detected for ARX from our risks checks.

View all Risks and Rewards
Page 1 of 1